PathoScan hrHPV
Commercial- Indications
- HPV infection, Cervical cancer
Company intelligence / Profile preview
Nusantics is Indonesia’s leading precision molecular diagnostics company. Their technology has been used in over 8 million COVID‑19 tests. They have developed non-invasive sampling methods and rapid variant screening tools for COVID‑19. The company is expanding into broader infectious disease and oncology testing as well as animal health applications. No clinical trial results are reported since the focus is on commercialized diagnostic products.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nusantics.